IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.994
NA - Nord America 835
EU - Europa 729
SA - Sud America 371
AF - Africa 27
AN - Antartide 1
OC - Oceania 1
Totale 3.958
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 876
US - Stati Uniti d'America 778
CN - Cina 661
IT - Italia 320
BR - Brasile 314
HK - Hong Kong 277
DE - Germania 111
VN - Vietnam 86
GB - Regno Unito 54
RU - Federazione Russa 52
FI - Finlandia 50
NL - Olanda 41
CA - Canada 31
AR - Argentina 22
IN - India 22
AT - Austria 21
MX - Messico 20
PL - Polonia 20
SE - Svezia 17
BD - Bangladesh 15
ZA - Sudafrica 15
FR - Francia 14
JP - Giappone 12
CO - Colombia 10
EC - Ecuador 10
ES - Italia 8
ID - Indonesia 8
PY - Paraguay 6
UA - Ucraina 6
IQ - Iraq 5
UZ - Uzbekistan 5
PK - Pakistan 4
TR - Turchia 4
CR - Costa Rica 3
EG - Egitto 3
KE - Kenya 3
LT - Lituania 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BE - Belgio 2
CL - Cile 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
PH - Filippine 2
TW - Taiwan 2
UG - Uganda 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GY - Guiana 1
IE - Irlanda 1
JO - Giordania 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 3.958
Salva come PNG Salva come JPEG
Città #
Singapore 442
Hong Kong 277
Dallas 175
Shanghai 137
Hefei 106
Ashburn 104
Beijing 94
Milan 72
Boardman 45
Nuremberg 39
Ho Chi Minh City 36
São Paulo 35
Los Angeles 33
Rome 32
New York 28
Lappeenranta 24
Hanoi 21
Guangzhou 19
Warsaw 19
Helsinki 16
Moscow 16
Munich 16
Cesano Boscone 14
Poplar 14
Brescia 13
London 13
Atlanta 12
Brooklyn 12
Falkenstein 12
Santa Clara 12
Shenzhen 12
Mexico City 11
Denver 10
Johannesburg 10
Rio de Janeiro 10
Chennai 9
Chicago 9
Curitiba 9
Manchester 9
Montreal 9
Stockholm 9
Assago 8
Bari 8
Boston 8
Tokyo 8
Toronto 8
Vienna 8
Belo Horizonte 7
Brasília 7
Hangzhou 7
Orem 7
Phoenix 7
San Francisco 7
Turku 7
Wolfhagen 7
Amsterdam 6
Campinas 6
Jiaxing 6
Venice 6
Baghdad 5
Calgary 5
Comun Nuovo 5
Lawrence 5
Princeton 5
Reston 5
Verona 5
Xuzhou 5
Asunción 4
Bologna 4
Dhaka 4
Florence 4
Frankfurt am Main 4
Genoa 4
Joinville 4
Naples 4
Paris 4
Porto Alegre 4
Quanzhou 4
St Louis 4
Stezzano 4
São José dos Campos 4
Tashkent 4
Ankara 3
Annapolis 3
Belém 3
Bogotá 3
Buffalo 3
Cagliari 3
Cairo 3
Charlotte 3
Cipolletti 3
Contagem 3
Cornaredo 3
Costa de' Nobili 3
Da Nang 3
Lahore 3
Ottawa 3
Ourinhos 3
Pelotas 3
Pisa 3
Totale 2.277
Salva come PNG Salva come JPEG
Nome #
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 109
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 104
Spatial predictors of immunotherapy response in triple-negative breast cancer 69
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 64
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 63
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 62
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 62
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 60
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 60
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 59
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 59
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 58
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 58
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 58
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 56
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 56
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 56
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 56
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 55
PARP Inhibitors for Breast Cancer Treatment: A Review 55
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 55
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 52
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 52
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 52
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 52
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 51
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 51
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 50
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 49
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 49
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 49
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 48
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 47
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 47
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 44
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 43
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 43
An unmet need: tailoring extended adjuvant endocrine therapy. 42
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 42
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 42
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 41
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 40
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 39
Immunological differences between primary and metastatic breast cancer 39
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 39
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 38
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 37
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 37
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 36
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 36
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 36
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 36
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 35
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 35
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 35
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 35
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 34
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 34
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 33
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 33
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 32
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 32
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 31
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 31
[18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial 31
Somatostatin response to a mixed meal in normals and in type I diabetics 30
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 30
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 29
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 29
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 29
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 29
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. 29
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 29
Is trastuzumab as a single agent obsolete in early breast cancer? No 27
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 27
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 27
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 27
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 27
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 27
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 27
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 26
Treatment options in hormone-refractory metastatic prostate carcinoma. 26
Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis 26
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer 26
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial 26
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 26
Molecular heterogeneity of estrogen receptor-positive breast cancer explains variable and contradictory results of randomized adjuvant chemotherapy trials in breast cancer 26
OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. 25
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. 25
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer? 25
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 25
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief 24
Surrogate markers for targeted therapy-based treatment activity and efficacy. 24
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 24
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. 24
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers 23
HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry? 23
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 23
The immune system and response to HER2-targeted treatment in breast cancer. 23
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 22
Totale 4.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.441
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.441
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 1 1 0 0 0 0 0
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024205 0 0 3 3 1 42 12 8 1 3 61 71
2024/20251.789 239 82 15 97 164 150 288 215 234 98 92 115
2025/20262.164 353 389 273 653 459 37 0 0 0 0 0 0
Totale 4.186